Distinct gene expression-defined classes of gastrointestinal stromal tumor

Umio Yamaguchi, Turrent Robert Nakayama, Kazufumi Honda, Hitoshi Ichikawa, Tadashi Hasegawa, Miki Shitashige, Masaya Ono, Ayako Shoji, Tomohiro Sakuma, Hideya Kuwabara, Yasuhiro Shimada, Mitsuru Sasako, Tadakazu Shimoda, Akira Kawai, Setsuo Hirohashi, Tesshi Yamada

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Purpose: The majority of gastrointestinal stromal tumors (GIST) can be cured by surgery alone, but relapse occurs in 20% to 40% of cases. GISTs are considered to invariably arise through gain of function KIT or PDGFA mutation of the interstitial cells of Cajal (ICC). However, the genetic basis of the malignant progression of GISTs are poorly understood. Patients and Methods: The expression levels of 54,613 probe sets in 32 surgical samples of untreated GISTs of the stomach and small intestine were analyzed with oligonucleotide microarrays. The representative GeneChip data were validated by real-time reverse transcriptase polymerase chain reaction and immunohistochemistry. Results: Unbiased hierarchical clustering consistently separated the 32 cases of GIST into two major classes according to tumor site. The two major classes were further separated into novel subclasses, which were significantly correlated with various pathological prognostic parameters, the frequency of metastasis (P < .05), and clinical outcome. Immunohistochemical analysis of 152 independent patients with gastric GISTs revealed that the expression of dipeptidyl peptidase IV (T-cell activation antigen CD26) protein was significantly associated with poorer overall and disease-free survival (P < .00001). Conclusion: CD26 appears to be a reliable biomarker of malignant GISTs of the stomach. The postoperative recurrence rate of CD26-negative cases was as low as 2.0% (two of 102). Therefore, postoperative follow-up of such patients might be made less intensive. CD26 may play an important role in the malignant progression of gastric GISTs and serve as a therapeutic target.

Original languageEnglish
Pages (from-to)4100-4108
Number of pages9
JournalJournal of Clinical Oncology
Volume26
Issue number25
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Stomach
Gene Expression
CD27 Antigens
Interstitial Cells of Cajal
Dipeptidyl Peptidase 4
Recurrence
Oligonucleotide Array Sequence Analysis
Reverse Transcriptase Polymerase Chain Reaction
Disease-Free Survival
Small Intestine
Cluster Analysis
Real-Time Polymerase Chain Reaction
Biomarkers
Immunohistochemistry
Neoplasm Metastasis
Mutation
Neoplasms
Proteins
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamaguchi, U., Nakayama, T. R., Honda, K., Ichikawa, H., Hasegawa, T., Shitashige, M., ... Yamada, T. (2008). Distinct gene expression-defined classes of gastrointestinal stromal tumor. Journal of Clinical Oncology, 26(25), 4100-4108. https://doi.org/10.1200/JCO.2007.14.2331

Distinct gene expression-defined classes of gastrointestinal stromal tumor. / Yamaguchi, Umio; Nakayama, Turrent Robert; Honda, Kazufumi; Ichikawa, Hitoshi; Hasegawa, Tadashi; Shitashige, Miki; Ono, Masaya; Shoji, Ayako; Sakuma, Tomohiro; Kuwabara, Hideya; Shimada, Yasuhiro; Sasako, Mitsuru; Shimoda, Tadakazu; Kawai, Akira; Hirohashi, Setsuo; Yamada, Tesshi.

In: Journal of Clinical Oncology, Vol. 26, No. 25, 2008, p. 4100-4108.

Research output: Contribution to journalArticle

Yamaguchi, U, Nakayama, TR, Honda, K, Ichikawa, H, Hasegawa, T, Shitashige, M, Ono, M, Shoji, A, Sakuma, T, Kuwabara, H, Shimada, Y, Sasako, M, Shimoda, T, Kawai, A, Hirohashi, S & Yamada, T 2008, 'Distinct gene expression-defined classes of gastrointestinal stromal tumor', Journal of Clinical Oncology, vol. 26, no. 25, pp. 4100-4108. https://doi.org/10.1200/JCO.2007.14.2331
Yamaguchi, Umio ; Nakayama, Turrent Robert ; Honda, Kazufumi ; Ichikawa, Hitoshi ; Hasegawa, Tadashi ; Shitashige, Miki ; Ono, Masaya ; Shoji, Ayako ; Sakuma, Tomohiro ; Kuwabara, Hideya ; Shimada, Yasuhiro ; Sasako, Mitsuru ; Shimoda, Tadakazu ; Kawai, Akira ; Hirohashi, Setsuo ; Yamada, Tesshi. / Distinct gene expression-defined classes of gastrointestinal stromal tumor. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 25. pp. 4100-4108.
@article{6fe50f5f49d34d50aa769912a8b83c7a,
title = "Distinct gene expression-defined classes of gastrointestinal stromal tumor",
abstract = "Purpose: The majority of gastrointestinal stromal tumors (GIST) can be cured by surgery alone, but relapse occurs in 20{\%} to 40{\%} of cases. GISTs are considered to invariably arise through gain of function KIT or PDGFA mutation of the interstitial cells of Cajal (ICC). However, the genetic basis of the malignant progression of GISTs are poorly understood. Patients and Methods: The expression levels of 54,613 probe sets in 32 surgical samples of untreated GISTs of the stomach and small intestine were analyzed with oligonucleotide microarrays. The representative GeneChip data were validated by real-time reverse transcriptase polymerase chain reaction and immunohistochemistry. Results: Unbiased hierarchical clustering consistently separated the 32 cases of GIST into two major classes according to tumor site. The two major classes were further separated into novel subclasses, which were significantly correlated with various pathological prognostic parameters, the frequency of metastasis (P < .05), and clinical outcome. Immunohistochemical analysis of 152 independent patients with gastric GISTs revealed that the expression of dipeptidyl peptidase IV (T-cell activation antigen CD26) protein was significantly associated with poorer overall and disease-free survival (P < .00001). Conclusion: CD26 appears to be a reliable biomarker of malignant GISTs of the stomach. The postoperative recurrence rate of CD26-negative cases was as low as 2.0{\%} (two of 102). Therefore, postoperative follow-up of such patients might be made less intensive. CD26 may play an important role in the malignant progression of gastric GISTs and serve as a therapeutic target.",
author = "Umio Yamaguchi and Nakayama, {Turrent Robert} and Kazufumi Honda and Hitoshi Ichikawa and Tadashi Hasegawa and Miki Shitashige and Masaya Ono and Ayako Shoji and Tomohiro Sakuma and Hideya Kuwabara and Yasuhiro Shimada and Mitsuru Sasako and Tadakazu Shimoda and Akira Kawai and Setsuo Hirohashi and Tesshi Yamada",
year = "2008",
doi = "10.1200/JCO.2007.14.2331",
language = "English",
volume = "26",
pages = "4100--4108",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Distinct gene expression-defined classes of gastrointestinal stromal tumor

AU - Yamaguchi, Umio

AU - Nakayama, Turrent Robert

AU - Honda, Kazufumi

AU - Ichikawa, Hitoshi

AU - Hasegawa, Tadashi

AU - Shitashige, Miki

AU - Ono, Masaya

AU - Shoji, Ayako

AU - Sakuma, Tomohiro

AU - Kuwabara, Hideya

AU - Shimada, Yasuhiro

AU - Sasako, Mitsuru

AU - Shimoda, Tadakazu

AU - Kawai, Akira

AU - Hirohashi, Setsuo

AU - Yamada, Tesshi

PY - 2008

Y1 - 2008

N2 - Purpose: The majority of gastrointestinal stromal tumors (GIST) can be cured by surgery alone, but relapse occurs in 20% to 40% of cases. GISTs are considered to invariably arise through gain of function KIT or PDGFA mutation of the interstitial cells of Cajal (ICC). However, the genetic basis of the malignant progression of GISTs are poorly understood. Patients and Methods: The expression levels of 54,613 probe sets in 32 surgical samples of untreated GISTs of the stomach and small intestine were analyzed with oligonucleotide microarrays. The representative GeneChip data were validated by real-time reverse transcriptase polymerase chain reaction and immunohistochemistry. Results: Unbiased hierarchical clustering consistently separated the 32 cases of GIST into two major classes according to tumor site. The two major classes were further separated into novel subclasses, which were significantly correlated with various pathological prognostic parameters, the frequency of metastasis (P < .05), and clinical outcome. Immunohistochemical analysis of 152 independent patients with gastric GISTs revealed that the expression of dipeptidyl peptidase IV (T-cell activation antigen CD26) protein was significantly associated with poorer overall and disease-free survival (P < .00001). Conclusion: CD26 appears to be a reliable biomarker of malignant GISTs of the stomach. The postoperative recurrence rate of CD26-negative cases was as low as 2.0% (two of 102). Therefore, postoperative follow-up of such patients might be made less intensive. CD26 may play an important role in the malignant progression of gastric GISTs and serve as a therapeutic target.

AB - Purpose: The majority of gastrointestinal stromal tumors (GIST) can be cured by surgery alone, but relapse occurs in 20% to 40% of cases. GISTs are considered to invariably arise through gain of function KIT or PDGFA mutation of the interstitial cells of Cajal (ICC). However, the genetic basis of the malignant progression of GISTs are poorly understood. Patients and Methods: The expression levels of 54,613 probe sets in 32 surgical samples of untreated GISTs of the stomach and small intestine were analyzed with oligonucleotide microarrays. The representative GeneChip data were validated by real-time reverse transcriptase polymerase chain reaction and immunohistochemistry. Results: Unbiased hierarchical clustering consistently separated the 32 cases of GIST into two major classes according to tumor site. The two major classes were further separated into novel subclasses, which were significantly correlated with various pathological prognostic parameters, the frequency of metastasis (P < .05), and clinical outcome. Immunohistochemical analysis of 152 independent patients with gastric GISTs revealed that the expression of dipeptidyl peptidase IV (T-cell activation antigen CD26) protein was significantly associated with poorer overall and disease-free survival (P < .00001). Conclusion: CD26 appears to be a reliable biomarker of malignant GISTs of the stomach. The postoperative recurrence rate of CD26-negative cases was as low as 2.0% (two of 102). Therefore, postoperative follow-up of such patients might be made less intensive. CD26 may play an important role in the malignant progression of gastric GISTs and serve as a therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=51649106775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649106775&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.2331

DO - 10.1200/JCO.2007.14.2331

M3 - Article

C2 - 18757323

AN - SCOPUS:51649106775

VL - 26

SP - 4100

EP - 4108

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -